跳至主要内容
临床试验/EUCTR2014-000586-45-BE
EUCTR2014-000586-45-BE进行中(未招募)1 期

Oxytocin-based pharmacotherapy for Autism Spectrum Disorders:Investigating the neural and behavioral effects of a promising interventionapproach - Oxytocin study

KU Leuven0 个研究点目标入组 40 人开始时间: 2014年3月27日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
KU Leuven
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Male

入选标准

  • Young male adult participants with autism spectrum disorder will be
  • recruited mainly from the Expertise Centrum Autisme (ECA) of the UZ
  • Leuven, Belgium.
  • Participants are selected when diagnosed with ASD by a
  • multidisciplinary team of experienced clinicians as defined by the DSMIV-
  • TR (or DSM-V) criteria (Diagnostic and Statistical Manual of Mental
  • Disorders). In addition to the DSM-criteria, the Developmental
  • Dimensional Diagnostic instrument (3DI, David Skuse) and the Autism
  • Diagnostic Observation Schedule (ADOS) will be adopted as diagnostic
  • Participants within an age-range of 18-30 will be included.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 80
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Participants will be excluded based on the following criteria:
  • (i) associated psychiatric or neurological disorders (e.g. ADHD),
  • (ii) use of psychotropic medication,
  • (iii) any contraindication to neuroimaging research as assessed with the
  • MRI screening list (see below)
  • MRI contraindications
  • pacemaker, implanted defibrillator, ear implant / a cochlear implant,
  • insulin or implanted pump, a neurostimulator or VP shunt, any metallic
  • object in the eyes (metallic fragments)

研究者

发起方
KU Leuven

相似试验